R. Kaplan

Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8351.

M. Rybak, J. Anderson, R. Kaplan, 1993, Medical and Pediatric Oncology.

ICON8: A GCIG phase III randomised trial evaluating weekly dosedense chemotherapy integration in first- line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis

J. Brenton, J. Ledermann, I. McNeish, 2017 .

Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.

S. Pannullo, A. Tsiouris, J. Boockvar, 2012, Journal of experimental therapeutics & oncology.

Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

E. Frangou, M. Stockler, J. Bellmunt, 2019, Annals of Oncology.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

D. Lambrechts, M. D. James, J. Bridgewater, 2011, The Lancet.

Phase II trial of etoposide and cis-diaminodichloro-platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and Leukemia Group B (CALGB) Study 8353.

K. Propert, M. Rybak, R. Kaplan, 1990, Medical and pediatric oncology.